Jean D. Sifleet, Esq., CPA is the head of the Business Practice Group law firm. With her extensive business background, Jean provides practical, outcome-focused advice to business owners. Jean is the author of numerous articles and several books, including: “Beyond 401(k)s for Small Business Owners” (Wiley 2004) and “Advantage IP – Profit from Your Great Ideas” (Infinity 2006). By working with Jean and her colleagues, owners of privately held companies receive a broad range of services – from business formation through ownership transition – with an emphasis on implementing smart business practices to avoid problems, and using legal strategies to protect their interests. Jean has extensive experience with corporate, contract, intellectual property (including copyrights, trademarks, and licensing), employment and business succession (exit) planning. She is interviewed here by QRCA VIEWS Business Matters Editor, Kay Corry Aubrey.
Related Articles

Exploring the Metaverse: A New Realm for Qualitative Research?
Insights from the Best Paper at ESOMAR Congress 2023 exploring the metaverse as an opportunity for qualitative research. The authors detail their efforts to investigate the metaverse’s potential for market research, outlining the goals, research tasks, and challenges they encountered. […]

Here for the Incentive: Recognizing and Rooting out Fake Respondents
With an increase of “research fraud” that has accompanied the move to online methodologies, combined with the historical context of Will Leitch’s published guidance to would-be research cheaters, we discuss concrete strategies for mitigating fraud with experienced qualitative and UX researchers. […]

Expanding Your Business into Pharmaceutical Market Research
Pharmaceutical research is so rewarding—you’re contributing to the greater good of your communities—but it is also a very demanding industry to work in. In this article, we share the rewards, challenges, and scenarios in this field, so that you too might explore expanding your business into the vibrancy of pharma research. […]
Be the first to comment